CARBOPLATIN
| Brand name | KYXATA |
|---|---|
| Active ingredient | CARBOPLATIN |
| Strength | 80MG/8ML (10MG/ML) |
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Modality | Small molecule |
| FDA approval | August 2025 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 12427104 | April 2045 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.